let's recode what's possible
our first approval!June 03, 2019
The flock receives EU Conditional Marketing Authorization for our first product, ZYNTEGLO™ (autologous CD34+ cells encoding βA-T87Q-globin gene)
We Receive Positive CHMP OpinionMarch 29, 2019
bRT Ribbon CuttingMarch 21, 2019
Our nest in North Carolina is open for business!
We Announce A Partnership With InhibrixJanuary 07, 2019
bluebird bio announces exclusive license agreement to research, develop and commercialize chimeric antigen receptor (CAR) T cell therapies using Inhibrx’s proprietary single domain antibody (sdAb) platform to multiple cancer targets.
Our Regulatory Application Is Accepted By The EMAOctober 05, 2018
bluebird bio announces European Medicines Agency’s Acceptance of Marketing Authorization Application of our investigational treatment for patients with transfusion-dependent β-thalassemia.
We Announce Partnership With Gritstone Oncology, Inc.August 23, 2018
bluebird bio announces a collaboration to research, develop and commercialize products for the treatment of cancer using cell therapy.
Strategic Collaboration With Regeneron AnnouncedAugust 06, 2018
bluebird bio announces collaboration with Regeneron to discover, develop and commercialize new cell therapies for cancer
FDA Grants Us Breakthrough Therapy Designation In ALDMay 23, 2018
bluebird's investigational gene therapy for cerebral ALD was granted Breakthrough Therapy designation by the U.S. FDA.
Our First Superstar DayMay 20, 2018
Each bird is allowed to invite 1-2 people that inspire them to visit the office and to see what we do here on behalf of patients. Our speaker and performer for year one was America’s Got Talent contestant, Mandy Harvey.
Strategic Collaboration With TC Biopharma AnnouncedDecember 07, 2017
Collaboration with TC Biopharma announced to research and develop Gamma Delta CAR T cell product candidates for cancer immunotherapy
We Move To The Newest Nest!March 21, 2017
Our Facilities team celebrates after receiving the Certificate of Occupancy for our new nest at 60 Binney, Cambridge MA.
We Enter Into A Partnership With Apceth BiopharmaDecember 15, 2016
Our manufacturing relationship with Apceth provides us with European commercial manufacturing capabilities
R&D Collaboration With Medigene AnnouncedSeptember 29, 2016
bluebird bio announces strategic research and development collaboration and licensing agreement with Medigene AG for T cell receptor (TCR) immunotherapies against four targets.
We Receive PRIME Designation By The EMASeptember 21, 2016
Our investigational treatment for patient with transfusion-dependent β-thalassemia was given PRIME designation by European Medicines Agency (EMA)
We Enter Into A Strategic Agreement With LonzaJune 09, 2016
bluebird bio announces strategic manufacturing agreement with Lonza Houston, Inc., providing for future commercial production of our drug products
Our First EU Bird Joins The NestJune 06, 2016
Gabriella joined the nest as our first hire in Italy. We now have EU birds in Switzerland, Italy, France, the Netherlands, and the UK too!
Daron's bluebird DayApril 29, 2016
bluebird invites Daron, a 12 year old boy fighting cancer, to be our Chief Scientific Officer for the day! All birds fly with Daron!
First Multiple Myeloma Patient TreatedFebruary 17, 2016
First patient treated with bb2121 anti-BCMA CAR T cell therapy in Phase 1 study in patients with relapsed/refractory multiple myeloma.
First Sickle Cell Disease Patient TreatedOctober 14, 2014
The first patient treated in a clinical study of our investigational treatment for sickle cell disease was a milestone for bbb and patients.
First Transfusion-Dependent β-thalassemia Patient TreatedMay 03, 2014
The first patient treated in a clinical study of our investigational treatment for β-thalassemia was a milestone for bbb and patients.
We Move to 150 Second Street in CambridgeDecember 29, 2013
As bluebird continues to grow, the team moves to their new nest at 150 Second Street in Cambridge.
First Ever bbb Auction!September 18, 2013
The all-employee auction has become an annual bluebird tradition. Each year, employees donate and bid on items to raise money for the charity of our choosing including the Ethan Zakes Foundation, Brian’s Hope, Sickle Cell Community Consortium, Thalassemia Support Foundation and most recently in 2018 for Stupid Cancer.
We Acquire PregenenJune 30, 2013
bluebird expands to the West Coast by acquiring some kick-ass birds with a unique gene editing platform. We now have a nest in Seattle, WA.
$BLUE Goes PublicJune 19, 2013
bluebird's initial public offering (IPO)
Collaboration with Celgene AnnouncedMarch 15, 2013
bluebird collaborates with Celgene to discover, develop and commercialize novel, disease-altering gene therapies in oncology.
First Participation in BioBallApril 28, 2012
BioBall is a one day basketball tournament that partners with the Mass Bio-Tech community to raise money for Special Olympics Massachusetts. - BioBall is now an annual tradition for bluebird.
Founding Day of bluebird bioSeptember 09, 2010
Genetix becomes bluebird
Genetix FoundedApril 16, 1992